About Glycerol-3-phosphate acyltransferase 4
Glycerol-3-phosphate acyltransferase 4 (GPAT4) is a protein
from Homo sapiens identified by UniProt accession
Q86UL3, 456 residues long.
MolForge cross-references it against 0 known binders and
29 disease associations.
Target properties
| Protein name | Glycerol-3-phosphate acyltransferase 4 |
| UniProt accession | Q86UL3 |
| Gene | GPAT4 |
| Organism | Homo sapiens |
| Length | 456 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (29)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.18
- breast adenocarcinoma · score 0.18
- mean platelet volume · score 0.09
- mean corpuscular volume · score 0.04
- type 2 diabetes mellitus · score 0.04
- Obesity · score 0.03
- nonpapillary renal cell carcinoma · score 0.03
- inherited lipid metabolism disorder · score 0.02
- Insulin resistance · score 0.01
- Sepsis · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86UL3-F1 | alphafold | PREDICTED | 85.34 | — |
Amino-acid sequence (456 residues)
MFLLLPFDSL IVNLLGISLT VLFTLLLVFI IVPAIFGVSF GIRKLYMKSL LKIFAWATLR MERGAKEKNH QLYKPYTNGI IAKDPTSLEE EIKEIRRSGS SKALDNTPEF ELSDIFYFCR KGMETIMDDE VTKRFSAEEL ESWNLLSRTN YNFQYISLRL TVLWGLGVLI RYCFLLPLRI ALAFTGISLL VVGTTVVGYL PNGRFKEFMS KHVHLMCYRI CVRALTAIIT YHDRENRPRN GGICVANHTS PIDVIILASD GYYAMVGQVH GGLMGVIQRA MVKACPHVWF ERSEVKDRHL VAKRLTEHVQ DKSKLPILIF PEGTCINNTS VMMFKKGSFE IGATVYPVAI KYDPQFGDAF WNSSKYGMVT YLLRMMTSWA IVCSVWYLPP MTREADEDAV QFANRVKSAI ARQGGLVDLL WDGGLKREKV KDTFKEEQQK LYSKMIVGNH KDRSRS
Explore Glycerol-3-phosphate acyltransferase 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets